Meritage Portfolio Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.9M | Buy |
60,398
+1,595
| +3% | +$50.3K | 0.12% | 162 |
|
|
2025
Q1 | $1.93M | Buy |
58,803
+10,622
| +22% | +$348K | 0.13% | 163 |
|
|
2024
Q4 | $1.74M | Buy |
48,181
+3,886
| +9% | +$141K | 0.11% | 170 |
|
|
2024
Q3 | $1.38M | Buy |
44,295
+4,328
| +11% | +$135K | 0.08% | 182 |
|
|
2024
Q2 | $1.07M | Buy |
39,967
+315
| +0.8% | +$8.43K | 0.07% | 197 |
|
|
2024
Q1 | $1.35M | Sell |
39,652
-3,288
| -8% | -$112K | 0.09% | 185 |
|
|
2023
Q4 | $1.24M | Buy |
42,940
+6,873
| +19% | +$199K | 0.08% | 182 |
|
|
2023
Q3 | $994K | Buy |
36,067
+19,372
| +116% | +$534K | 0.07% | 196 |
|
|
2023
Q2 | $502K | Buy |
16,695
+4,020
| +32% | +$121K | 0.04% | 244 |
|
|
2023
Q1 | $459K | Buy |
12,675
+74
| +0.6% | +$2.68K | 0.03% | 218 |
|
|
2022
Q4 | $449K | Buy |
12,601
+365
| +3% | +$13K | 0.04% | 217 |
|
|
2022
Q3 | $414K | Buy |
12,236
+524
| +4% | +$17.7K | 0.03% | 224 |
|
|
2022
Q2 | $339K | Sell |
11,712
-301
| -3% | -$8.71K | 0.03% | 236 |
|
|
2022
Q1 | $388K | Buy |
12,013
+1,072
| +10% | +$34.6K | 0.02% | 237 |
|
|
2021
Q4 | $319K | Buy |
10,941
+780
| +8% | +$22.7K | 0.02% | 253 |
|
|
2021
Q3 | $271K | Buy |
10,161
+630
| +7% | +$16.8K | 0.02% | 254 |
|
|
2021
Q2 | $293K | Buy |
9,531
+1,512
| +19% | +$46.5K | 0.02% | 254 |
|
|
2021
Q1 | $210K | Buy |
+8,019
| New | +$210K | 0.01% | 270 |
|